Beta-aminopropylbenzene and beta-aminoisopropylbenzene
No structure available
Beta-aminopropylbenzene and beta-aminoisopropylbenzene could not be matched to a single known compound.
Background
Listing
- Schedules
- Schedule 5 to 7, conditions apply
- Exceptions reach
- Schedule 1 and 2
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
The ingredient index links no registered medicine to Beta-aminopropylbenzene and beta-aminoisopropylbenzene (register of 13 September 2026).
Counted through the register's ingredient index, which does not reach every record.
Regulatory status
Where S5 to S7 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 5: prescription-only, with tighter controls on repeats. At the most restrictive, Schedule 7: prohibited outside a government permit. The listings below say which applies to which form, strength or pack size.
Schedule S5 to S7, as the Consolidated Schedules list it.
Who may supply: Nobody, except under a permit issued by the Director-General. The Director-General may also authorise a medical practitioner, analyst, researcher or veterinarian to acquire or use it, on prescribed conditions, for the treatment or prevention of a medical condition in a particular patient, or for education, analysis or research. An ordinary prescription does not apply.
Consolidated Schedules listings for Beta-aminopropylbenzene and beta-aminoisopropylbenzene
S7: Beta-aminopropylbenzene and beta-aminoisopropylbenzene
- except any compound structurally derived from either beta-aminopropylbenzene or beta-aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure); and presented as:
- except preparations and mixtures when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and
- except appliances for inhalation in which the substance is absorbed onto solid material; (S1)
- except excluding cathine ((+)-norpseudoephedrine), ephedrine, etafedrine, N-methylephedrine, N-diethylaminoethylephedrine, phenylpropanolamine, prenylamine; (S1, S2, S5)
- except substances listed in S1, S2, S5, and S6.
Consolidated Schedules 06 July 2026, lines 10588 to 10600
S5: Beta-aminopropylbenzene and beta-aminoisopropylbenzene
- any compound structurally derived from either of these substances by substitution in the side chain or by ring closure therein (or by both such substitution and such ring closure); and
- any salt or substance falling under the above, and
- except preparations and mixtures of the above when used as vasoconstrictors and decongestants in antihistamine nose and eye preparations; (S1) and
- except when contained in appliances for inhalation in which the substance is absorbed onto solid material; (S1, S7) and
- except excluding cathine ((+)-norpseudoephedrine), ephedrine, etafedrine, N-methylephedrine, N-diethylaminoethylephedrine, phenylpropanolamine, prenylamine and preparations and mixtures thereof; and
- except substances listed in Schedule 7. (S1, S2, S6)
Consolidated Schedules 06 July 2026, lines 9245 to 9267
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.